Medregen is proud to announce that the results of the phase I study (NCT04646603) have been published in Cell Reports Medicine. MRG-001 demonstrated excellent safety and tolerability across all dose-ranges. For the full report, please refer to the publications section. This article is published as open access, ensuring it is freely available to everyone without subscription or payment barriers. Readers can access the full text to explore the findings and insights without restrictions.
19
Sep
